Date: 2016-02-25
Type of information: Grant
Company: Cobra Biologics (Sweden) The Centre for Process Innovation (UK)
Investors: Innovate UK (UK)
Amount: £1.4 million
Funding type: grant
Planned used: The collaboration between Cobra and CPI will focus on AAV vectors which are safe and effective and are currently the delivery vehicle of choice for gene therapy treatments. The proposed collaboration between Cobra and CPI will develop in depth scientific and technical understanding to allow a scalable and flexible manufacturing process to be developed to produce, purify and characterise a range of AAV vectors.
Others: * On February 25, 2016, Cobra Biologics and the Centre for Process Innovation (CPI) announced that they have been awarded a grant to support their project focused on the development of an industrial manufacturing platform for Adeno-Associated Virus (AAV) production to support gene therapy and regenerative medicine. The £1.8M project, which is being led by Cobra, is being funded to a value of £1.4M by Innovate UK via their 2015 competition for the development of regenerative medicines and cell therapies. The project is one of five which together comprise an £8 million investment into collaborative R&D projects that address critical challenges faced by UK companies developing regenerative medicines and cell therapies as clinical treatments and commercial products.
Therapeutic area: Technology - Services
